Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review DOI

VEENA V. TOM,

A. De la Fuente Hernández José, Sumit Mallick

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Language: Английский

Overcoming immune evasion with innovative multi-target approaches for glioblastoma DOI Creative Commons
Hai Su, Peng Yin, Yi‐Long Wu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 22, 2025

Glioblastoma (GBM) cells leverage complex endogenous and environmental regulatory mechanisms to drive proliferation, invasion, metastasis. Tumor immune evasion, facilitated by a multifactorial network, poses significant challenge effective therapy, as evidenced the limited clinical benefits of monotherapies, highlighting adaptive nature evasion. This review explores glioblastoma’s evasion mechanisms, role ICIs in tumor microenvironment, recent advancements, offering theoretical insights directions for monotherapy combination therapy glioblastoma management.

Language: Английский

Citations

1

Role of liposomes in chemoimmunotherapy of Breast cancer DOI

Fatemeh Attarian,

Ghazaleh Hatamian,

Shamim Nosrati

et al.

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 43

Published: Feb. 19, 2025

In the dynamic arena of cancer therapeutics, chemoimmunotherapy has shown tremendous promise, especially for aggressive forms breast like triple-negative (TNBC). This review delves into significant role liposomes in enhancing effectiveness by leveraging cancer-specific mechanisms such as induction immunogenic cell death (ICD), reprogramming tumor microenvironment (TME), and enabling sequential drug release. We examine innovative dual-targeting that capitalize on heterogeneity, well pH-sensitive formulations offer improved control over delivery. Unlike prior analyses, this directly links advancements preclinical research-such PAMAM dendrimer-based nanoplatforms RGD-decorated liposomes-to clinical trial results, highlighting their potential to revolutionize TNBC treatment strategies. Additionally, we address ongoing challenges related scalability, toxicity, regulatory compliance, propose future directions personalized, immune-focused nanomedicine. work not only synthesizes latest research but also offers a framework translating liposomal from laboratory practice.

Language: Английский

Citations

0

Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review DOI

VEENA V. TOM,

A. De la Fuente Hernández José, Sumit Mallick

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Language: Английский

Citations

0